The simple use of HTA can not be an excuse for delays. Many countries using HTA deliver faster-funded access to medicine and other health technologies. Australia's issue is that its statutory framework for applying HTA to the PBS, which has been extended or used as the policy basis for other programs, was designed and intended to cause delays.
Delays were the intended outcome, not an unintended consequence
January 13, 2025 Latest NewsBioPharmaCommentNews of the Day
Latest Video
New Stories
-
It is profoundly wrong for any system to exclude compassion while outsourcing it to others
March 16, 2026 - - Latest News -
Scientists identify highly specific targets that could transform multiple myeloma treatment
March 15, 2026 - - Australian Biotech -
CSL Seqirus' adjuvanted flu vaccine approval extended to Australians aged 50 and over
March 15, 2026 - - Latest News -
GSK claims Pharma Cup as Kosi Challenge surpasses fundraising record
March 15, 2026 - - Latest News -
New program aims to make women’s health care more affordable and accessible
March 13, 2026 - - Latest News -
Australians turn to local pharmacies as frontline of everyday healthcare
March 13, 2026 - - Latest News -
Sandoz and Camp Quality unite to strengthen support for Australian families facing childhood cancer
March 13, 2026 - - Latest News

